BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34233640)

  • 1. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
    Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
    BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
    Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
    Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
    Martin RC; McFarland K; Ellis S; Velanovich V
    J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.
    Martin RC; McFarland K; Ellis S; Velanovich V
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S443-9. PubMed ID: 23128941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
    van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
    J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery.
    Heger U; Mack C; Tjaden C; Pan F; Pausch T; Hinz U; Sommer CM; Hackert T
    Pancreatology; 2021 Oct; 21(7):1349-1355. PubMed ID: 34404600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of locally advanced pancreatic cancer with irreversible electroporation - a Danish single center study of safety and feasibility.
    Flak RV; Stender MT; Jensen TM; Andersen KL; Henriksen SD; Mortensen PB; Sall M; Thorlacius-Ussing O
    Scand J Gastroenterol; 2019 Feb; 54(2):252-258. PubMed ID: 30907286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study.
    Paiella S; Butturini G; Frigerio I; Salvia R; Armatura G; Bacchion M; Fontana M; D'Onofrio M; Martone E; Bassi C
    Dig Surg; 2015; 32(2):90-7. PubMed ID: 25765775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial.
    Rai ZL; Ranieri V; Palmer DH; Littler P; Ghaneh P; Gurusamy K; Manas D; Pizzo E; Psarelli EE; Gilmore R; Peddu P; Bartlett DC; de Liguori Carino N; Davidson BR
    BMJ Open; 2022 May; 12(5):e050166. PubMed ID: 35551086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
    Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
    Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial.
    Walma MS; Rombouts SJ; Brada LJH; Borel Rinkes IH; Bosscha K; Bruijnen RC; Busch OR; Creemers GJ; Daams F; van Dam RM; van Delden OM; Festen S; Ghorbani P; de Groot DJ; de Groot JWB; Haj Mohammad N; van Hillegersberg R; de Hingh IH; D'Hondt M; Kerver ED; van Leeuwen MS; Liem MS; van Lienden KP; Los M; de Meijer VE; Meijerink MR; Mekenkamp LJ; Nio CY; Oulad Abdennabi I; Pando E; Patijn GA; Polée MB; Pruijt JF; Roeyen G; Ropela JA; Stommel MWJ; de Vos-Geelen J; de Vries JJ; van der Waal EM; Wessels FJ; Wilmink JW; van Santvoort HC; Besselink MG; Molenaar IQ;
    Trials; 2021 Apr; 22(1):313. PubMed ID: 33926539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma.
    Marsanic P; Mellano A; Sottile A; De Simone M
    Med Biol Eng Comput; 2017 Jul; 55(7):1123-1127. PubMed ID: 28078482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry.
    Holland MM; Bhutiani N; Kruse EJ; Weiss MJ; Christein JD; White RR; Huang KW; Martin RCG
    HPB (Oxford); 2019 Aug; 21(8):1024-1031. PubMed ID: 30737097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
    Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
    Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).
    Scheffer HJ; Vroomen LG; Nielsen K; van Tilborg AA; Comans EF; van Kuijk C; van der Meijs BB; van den Bergh J; van den Tol PM; Meijerink MR
    BMC Cancer; 2015 Oct; 15():772. PubMed ID: 26497813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
    Timmer FEF; Geboers B; Ruarus AH; Schouten EAC; Nieuwenhuizen S; Puijk RS; de Vries JJJ; Meijerink MR; Scheffer HJ
    Tech Vasc Interv Radiol; 2020 Jun; 23(2):100675. PubMed ID: 32591191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.